Iron Balance Study of Deferasirox, Deferoxamine and the Combination of Both
Weill Medical College of Cornell University
Phase 1/Phase 2
Subjects with thalassemia major require regular transfusion therapy to sustain life. The iron
present in the transfused blood remains in the body where it can cause a variety of organ
dysfunctions. Lifelong iron chelation therapy is needed to maintain iron balance but its
effectiveness varies greatly. Like that of deferoxamine (Desferal, DFO) the mainstay of
chelation therapy for 30 years, the effectiveness of deferasirox (Exjade, ICL670), the newly
approved, orally effective iron chelating drug, is not satisfactory in all subjects. Even
with good compliance, the iron excretion induced by a given drug exhibits wide
subject-to-subject variability. There is often persistent iron overload of extra hepatic
tissues such as the heart and pancreas leading to cardiac disease and diabetes. Combining the
drugs may be a better approach in those subjects at increased risk. The iron balance studies
proposed will permit an assessment of the potential of such a combination to place subjects
in net negative iron balance and the relative effectiveness of the combination in relation to
that of the individual drugs, an additive effect being expected. With such information,
physicians will be able to design individualized chelation regimens that maximize
effectiveness while minimizing side effects by adjusting the ratio and/or the dosing schedule
of the two drugs.
Comparison of Sublingual Misoprostol Versus Lidocaine Spray for Hysteroscopy
Dr. Sami Ulus Children's Hospital
Hysteroscopy is an instrument to visualize the interior walls of uterus (womb) and it enables
the doctor to do minor operative procedures. Although it causes little discomfort, sometimes
it may be disturbing for the patient. This pain is usually perceived during the passage of
the instrument through the cervix (neck of the womb). The investigators would like to
minimize this pain by two drugs: Misoprotol and lidocaine
Safety and Efficacy of Double Staining With Brilliant Blue G for Macular Surgery
Asociación para Evitar la Ceguera en México
Study designed to evaluate the safety and efficacy of double staining with brilliant blue G
0.025% as an adjuvant to macular surgery. Patients undergoing surgery for macular hole or
epiretinal membrane will be included. Safety will be evaluated by optic coherence tomography,
pattern reversal electroretinogram and multifocal electroretinogram.
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.